Study of Peripheral Blood CHI3L1 to Predict Tumor Response to Radiotherapy

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Jul 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a blood test measuring a protein called CHI3L1 can help predict how well tumors respond to radiotherapy, a common cancer treatment that uses radiation to kill cancer cells. Some tumors are resistant to radiotherapy, meaning the treatment doesn’t work as well, which can lead to the cancer coming back or getting worse. By checking CHI3L1 levels in the blood, doctors hope to identify patients whose tumors might not respond well to radiation before treatment starts, allowing for better and more personalized care.

The study is open to adults 18 years and older who have been diagnosed with certain types of cancer, including lung, breast, stomach, colorectal, brain, and several others, as long as they are generally in good health and able to undergo treatment. If you join the study, your blood will be tested to measure CHI3L1 levels before and during radiotherapy to see if this helps predict how your tumor responds. This is a non-invasive test, meaning it only requires a blood sample. The study is not yet recruiting participants, but it aims to provide important information that could improve cancer treatment in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Voluntarily signed informed consent form;
• • Age ≥ 18 years;
• • No restrictions on sex;
• • Histologically confirmed diagnosis of one of the following malignant tumors: nasopharyngeal carcinoma, head and neck cancer, lung cancer, breast cancer, gastric cancer, colorectal cancer, glioma, esophageal cancer, liver cancer, cholangiocarcinoma, cervical cancer, prostate cancer, or bladder cancer;
• • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
• Exclusion Criteria:
• • Patients with any serious comorbidities that may pose an unacceptable risk or adversely affect compliance with the study protocol. Examples include unstable heart disease requiring treatment, chronic hepatitis, renal disease with poor clinical status, uncontrolled diabetes mellitus (fasting blood glucose \> 1.5 × ULN), or psychiatric disorders.
• • Deemed unsuitable for participation in the study at the discretion of the investigators.